IP Library Granted Patent US 9,174,976
Granted Patent B2
US 9,174,976 · App. 14/289,573 · Granted Nov 3, 2015

Cyanoisoquinoline compounds and methods of use thereof

Inventors: Michael Arend (Foster City, CA); Lee A. Flippin (Woodside, CA); Min Wu (Sunnyvale, CA); Eric D. Turtle (Belmont, CA); Wen-Bin Ho (Los Altos, CA); Shaojiang Deng (San Mateo, CA)
Assignee: FIBROGEN, INC.
C07D417/12A61K31/435A61K31/44A61K31/47C07D217/26C07D405/12C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,174,976
App. No.
14/289,573
Granted
Nov 3, 2015
Kind
B2
Abstract

The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:

Claims (105)

1. A method for inhibiting a HIF hydroxylase in a subject, the method comprising administering to the subject a compound of formula I:

wherein:

R is selected from the group consisting of hydrogen, alkyl, and substituted alkyl;

R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, halo, cyano, hydroxyl, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, —OR 7 , —SR 7 , —SOR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

R 5 and R 6 are independently selected from the group consisting of hydrogen and C 1-3 alkyl;

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof; or an ester or amide of the carboxylic acid moiety on the glycine or alanine-based substituent of the cyanoisoquinoline ring.

2. The method of claim 1 , wherein the HIF hydroxylase is a HIF prolyl hydroxylase.

3. The method of claim 2 , wherein the prolyl hydroxylase is selected from the group consisting of human EGLN1, EGLN2, and EGLN3.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the subject is in need of treating, pretreating, or delaying onset of a condition associated with hypoxia inducible factor (HIF).

6. The method of claim 1 , wherein at least two of R 1 , R 2 , R 3 and R 4 are hydrogen.

7. The method of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, hydroxyl, halo, substituted alkyl, aryl, —OR 7 , —SR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

8. The method of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkoxy, aryloxy and substituted aryloxy.

9. The method of claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, hydroxyl, phenyl, chloro, trifluoromethyl, benzyl, benzyloxy, methoxy, butoxy, isopropoxy, phenoxy, 4-fluorophenoxy, 2-methoxyphenoxy, 3-methoxyphenoxy, 4-methoxyphenoxy, 2,6-dimethylphenoxy, 2-ethyl-6-methylphenoxy, 2,4,6-trimethylphenoxy, 4-chloro-2,6-dimethylphenoxy, 4-propoxyphenoxy, 2,3-dihydro-benzofuran-5-yloxy, 2-methyl-benzothiazol-6-yloxy, 2-dimethylamino-benzooxazol-5-yloxy, 2-morpholin-4-yl-benzothiazol-6-yloxy, 2-methyl-benzooxazol-6-yloxy, benzo[1,3]dioxo-5-yloxy, phenylsulfanyl, phenylsulfonyl, and cyclohexyloxy.

10. The method of claim 9 , wherein R 1 , R 3 and R 4 are hydrogen.

11. The method of claim 9 , wherein R 1 , R 2 and R 3 are hydrogen.

12. The method of claim 9 , wherein R 1 , R 2 , and R 4 are hydrogen.

13. The method of claim 9 , wherein R 2 , R 3 , and R 4 are hydrogen.

14. The method of claim 9 , wherein R 1 , R 2 , R 3 , and R 4 are hydrogen.

15. The method of claim 1 , wherein R 1 is selected from the group consisting of halo, cyano, hydroxyl, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, —OR 7 , —SR 7 , —SOR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

16. The method of claim 1 , where R 1 is selected from the group consisting of phenyl, phenoxy and 4-fluorophenoxy.

17. The method of claim 1 , wherein R 2 is selected from the group consisting of halo, cyano, hydroxyl, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, —OR 7 , —SR 7 , —SOR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

18. The method of claim 1 , wherein R 2 is selected from the group consisting of halo, —OR 7 , —SR 7 , —SOR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

19. The method of claim 18 , wherein R 2 is selected from the group consisting of chloro, methoxy, isopropoxy, phenoxy, 4-fluorophenoxy, 4-methoxyphenoxy, 2,6-dimethylphenoxy, 2-ethyl-6-methylphenoxy, 2,4,6-trimethylphenoxy, 4-chloro-2,6-dimethylphenoxy, 4-propoxyphenoxy, 2,3-dihydro-benzofuran-5-yloxy, 2-methyl-benzothiazol-6-yloxy, 2-dimethylamino-benzooxazol-5-yloxy, 2-morpholin-4-yl-benzothiazol-6-yloxy, 2-methyl-benzooxazol-6-yloxy, benzo[1,3]dioxo-5-yloxy, phenylsulfonyl, phenylsulfanyl, and cyclohexyloxy.

20. The method of claim 1 , wherein R 3 is selected from the group consisting of hydroxyl, halo, haloalkyl, substituted alkyl, —OR 7 , —SR 7 , —SOR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

21. The method of claim 20 , wherein R 3 is selected from the group consisting of trifluoromethyl, chloro, hydroxyl, benzyl, methoxy, isopropoxy, butoxy, benzyloxy, phenoxy, 4-fluorophenoxy, 2,6-dimethylphenoxy, 4-methoxyphenoxy, 2-dimethylamino-benzooxazol-5-yloxy, benzo[1,3]dioxo-5-yloxy, and phenylsulfanyl.

22. The method of claim 1 , wherein R 4 is selected from the group consisting of halo, cyano, hydroxyl, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, —OR 7 , —SR 7 , —SOR 7 , and —SO 2 R 7 wherein R 7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

23. The method of claim 1 , wherein R 4 is selected from the group consisting of phenyl, phenoxy, 2-methoxyphenoxy, 3-methoxyphenoxy, 4-methoxyphenoxy, and 4-fluorophenoxy.

24. The method of claim 1 , wherein R 5 is hydrogen.

25. The method of claim 1 , wherein R 5 is methyl.

26. The method of claim 1 , wherein R 6 is hydrogen.

27. The method of claim 1 , wherein R 6 is methyl.

28. The method of claim 1 , wherein R is hydrogen.

29. The method of claim 1 , wherein R is methyl.

30. The method of claim 1 , wherein the compound is of formula II:

wherein:

R 31 , R 32 , R 33 and R 34 are independently selected from the group consisting of hydrogen, cyano, hydroxyl, halo, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, —OR 37 , —SR 37 , —SOR 37 , and —SO 2 R 37 wherein R 37 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

R 35 is hydrogen or methyl;

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof; or an ester or amide of the carboxylic acid moiety on the glycine- or alanine-based substituent of the cyanoisoquinoline ring.

31. The method of claim 30 , wherein at least three of R 31 , R 32 , R 33 , and R 34 are hydrogen.

32. The method of claim 30 , wherein R 31 , R 32 , R 33 and R 34 are independently selected from the group consisting of hydrogen, halo, hydroxyl, alkyl, substituted alkyl, haloalkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, cycloalkoxy, substituted cycloalkoxy, amino, and substituted amino; and

R 35 is hydrogen or methyl.

33. The method of claim 32 , wherein R 31 , R 32 , R 33 and R 34 are independently selected from the group consisting of hydrogen, substituted alkyl, aryl, aryloxy, and substituted aryloxy; and R 35 is hydrogen or methyl.

34. The method of claim 33 , wherein R 31 , R 32 , R 33 and R 34 are independently selected from the group consisting of hydrogen, substituted alkyl, aryl, aryloxy, and aryloxy optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, alkoxy, and alkyl; and R 35 is hydrogen or methyl.

35. The method of claim 34 , wherein R 31 , R 32 , R 33 and R 34 are independently selected from the group consisting of hydrogen, phenoxy and phenoxy substituted with halogen; and R 35 is hydrogen or methyl.

36. The method of claim 35 , wherein one of R 31 , R 32 , R 33 and R 34 is phenoxy substituted with halogen, the other three of R 31 , R 32 , R 33 and R 34 are hydrogen, and R 35 is hydrogen.

37. The method of claim 36 , wherein R 31 is phenoxy substituted with halogen, R 32 , R 33 and R 34 are hydrogen, and R 35 is hydrogen.

38. The method of claim 36 , wherein R 32 is phenoxy substituted with halogen, R 31 , R 33 and R 34 are hydrogen, and R 35 is hydrogen.

39. The method of claim 36 , wherein R 33 is phenoxy substituted with halogen, R 31 , R 32 and R 34 are hydrogen, and R 35 is hydrogen.

40. The method of claim 36 , wherein R 34 is phenoxy substituted with halogen, R 31 , R 32 and R 33 are hydrogen, and R 35 is hydrogen.

41. The method of claim 1 , wherein the compound is selected from the group consisting of:

{[1-cyano-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

2-(S)-[(1-cyano-4-hydroxy-isoquinoline-3-carbonyl)-amino]-propionic acid,

{[1-cyano-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

2-(S)-[(1-cyano-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid,

2-(R)-[(1-cyano-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid,

{[1-cyano-7-(4-fluorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-7-(trifluoromethyl)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-7-chloro-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-8-phenoxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-8-(4-fluoro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(1-cyano-4-hydroxy-6-methoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-6-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

{[1-cyano-6-(4-fluoro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-6-(4-methoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(1-cyano-4-hydroxy-6-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-7-phenylsulfanyl-isoquinoline-3-carbonyl)-amino]-acetic acid,

{[1-cyano-6-(2,6-dimethyl-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(1-cyano-4-hydroxy-5-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

{[1-cyano-4-hydroxy-8-(4-methoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-8-(3-methoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-8-(2-methoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(7-benzyl-1-cyano-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

{[1-cyano-5-(4-fluoro-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-7-(2,6-dimethyl-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-6-(2-ethyl-6-methyl-phenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-6-(2,4,6-trimethyl-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[6-(4-chloro-2,6-dimethyl-phenoxy)-1-cyano-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-7-(4-methoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(1-cyano-6-cyclohexyloxy-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(6-benzenesulfonyl-1-cyano-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

{[1-cyano-4-hydroxy-6-(4-propoxy-phenoxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[7-(benzo[1,3]dioxol-5-yloxy)-1-cyano-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[6-(benzo[1,3]dioxol-5-yloxy)-1-cyano-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-6-(2,3-dihydro-benzofuran-5-yloxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(1-cyano-4-methoxy-8-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid methyl ester,

[(1-cyano-4-methoxy-8-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

(S)-2-[(1-cyano-4-hydroxy-8-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid,

(R)-2-[(1-cyano-4-hydroxy-8-phenoxy-isoquinoline-3-carbonyl)-amino]-propionic acid,

{[1-cyano-4-hydroxy-6-(2-methyl-benzothiazol-6-yloxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-6-(2-dimethylamino-benzooxazol-5-yloxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-7-(2-dimethylamino-benzooxazol-5-yloxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-6-(2-morpholin-4-yl-benzothiazol-6-yloxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

{[1-cyano-4-hydroxy-6-(2-methyl-benzooxazol-6-yloxy)-isoquinoline-3-carbonyl]-amino}-acetic acid,

[(6-chloro-1-cyano-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(7-butoxy-1-cyano-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-6,7-diphenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-7-methoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-7-isopropoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-6-isopropoxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-5-phenyl-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(1-cyano-4-hydroxy-8-phenyl-isoquinoline-3-carbonyl)-amino]-acetic acid,

[(7-benzyloxy-1-cyano-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

and [(1-cyano-4,7-dihydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid,

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof; or an ester or amide of the carboxylic acid moiety on the glycine- or alanine-based substituent of the cyanoisoquinoline ring.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2015
From: FLIPPIN, LEE A.; HO, WEN-BIN; TURTLE, ERIC D.; AREND, MICHAEL P.; DENG, SHAOJIANG; WU, MIN
To: FIBROGEN, INC.
Reel/Frame 034751/0802 →
Continuity (5)
Continuation 13430568 · Mar 26, 2012
Continuation 13042281 · Mar 7, 2011
Division 11627906 · Jan 26, 2007
Provisional Application 60762780 · Jan 27, 2006
Related Publication 20150031696A1 · Jan 29, 2015